Andrew Hotchkiss named president of Lilly's regional operations
This article was originally published in Scrip
Lilly has named Andrew Hotchkiss president for the Australia, Canada and Europe regions. Mr Hotchkiss has been with Lilly for 25 years, most recently serving as vice-president and international business unit leader for Lilly Oncology. He will succeed Karim Bitar, who will leave the company on 17 June 2011.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.